HomeCompareHSTXF vs ABBV

HSTXF vs ABBV: Dividend Comparison 2026

HSTXF yields 114.94% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HSTXF wins by $6.94M in total portfolio value
10 years
HSTXF
HSTXF
● Live price
114.94%
Share price
$1.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.05M
Annual income
$2,599,161.52
Full HSTXF calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — HSTXF vs ABBV

📍 HSTXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHSTXFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HSTXF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HSTXF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HSTXF
Annual income on $10K today (after 15% tax)
$9,770.11/yr
After 10yr DRIP, annual income (after tax)
$2,209,287.29/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, HSTXF beats the other by $2,187,761.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HSTXF + ABBV for your $10,000?

HSTXF: 50%ABBV: 50%
100% ABBV50/50100% HSTXF
Portfolio after 10yr
$3.58M
Annual income
$1,312,243.15/yr
Blended yield
36.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HSTXF
No analyst data
Altman Z
8.6
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HSTXF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHSTXFABBV
Forward yield114.94%3.09%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$7.05M$103.7K
Annual income after 10y$2,599,161.52$25,324.79
Total dividends collected$6.38M$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HSTXF vs ABBV ($10,000, DRIP)

YearHSTXF PortfolioHSTXF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$22,194$11,494.25$11,555$434.96+$10.6KHSTXF
2$47,590$23,841.72$13,485$635.47+$34.1KHSTXF
3$98,699$47,777.67$15,933$937.67+$82.8KHSTXF
4$198,214$92,606.18$19,118$1,400.80+$179.1KHSTXF
5$385,900$173,811.71$23,384$2,125.24+$362.5KHSTXF
6$729,168$316,254.64$29,290$3,286.81+$699.9KHSTXF
7$1,338,687$558,477.43$37,776$5,205.38+$1.30MHSTXF
8$2,390,633$958,237.97$50,495$8,488.44+$2.34MHSTXF
9$4,157,254$1,599,276.16$70,497$14,346.44+$4.09MHSTXF
10$7,047,423$2,599,161.52$103,718$25,324.79+$6.94MHSTXF

HSTXF vs ABBV: Complete Analysis 2026

HSTXFStock

Heliostar Metals Ltd. engages in the acquisition, exploration, and development of mineral properties in North America. It explores for gold and silver deposits. The company holds 100% interests in the Unga Gold project that covers an area of 240 square kilometers located in Alaska, the United States; and the Cumaro project in Mexico. It also has an option to acquire 100% interests in the Oso Negro and La Lola projects in Mexico. The company was formerly known as Redstar Gold Corp. and changed its name to Heliostar Metals Ltd. in October 2020. Heliostar Metals Ltd. was incorporated in 1983 and is based in Vancouver, Canada.

Full HSTXF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HSTXF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HSTXF vs SCHDHSTXF vs JEPIHSTXF vs OHSTXF vs KOHSTXF vs MAINHSTXF vs JNJHSTXF vs MRKHSTXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.